Real-World Safety of Vonoprazan in Patients and Symptom Outcomes in Patients With Reflux Esophagitis in China: A Prospective, Non-Interventional Study (VIEW)

Abstract

Objectives: Vonoprazan was approved in China for reflux esophagitis (RE) in 2019; however, its real-world safety and effectiveness remain undetermined. We aimed to evaluate the safety of vonoprazan in patients and its effectiveness in patients with RE in a real-world setting.

Methods: In this prospective, non-interventional, real-world study, vonoprazan 20 mg was administered orally daily for 4 or 8 weeks. Primary endpoints were incidence rates of adverse events (AEs), serious AEs (SAEs), and adverse drug reactions (ADRs). Secondary endpoints included proportions of patients with RE without typical gastroesophageal reflux disease (GERD) symptoms (complete symptom relief) at baseline and Week 4, relief of heartburn/regurgitation symptoms (all day/nighttime) during Week 1, and mean change in GERD Questionnaire (GERDQ) score at Week 4.

Results: Of the 2829 patients with safety data, 488 (17.2%) reported ≥ 1 AE; 29 (1.0%) reported ≥ 1 SAE; and 129 (4.6%) reported ≥ 1 ADR. Of 1796 patients with RE and effectiveness data, the proportion without typical symptoms of GERD increased from 20.1% (95% confidence interval [CI] 18.29–22.05) at baseline to 55.2% (95% CI 52.63–57.79) at Week 4 (change: 35.1%, 95% CI 31.95–38.25). Complete relief from heartburn, nighttime heartburn, regurgitation, and nighttime regurgitation was observed in 32.3% (314/971), 43.8% (427/975), 27.0% (262/971), and 40.5% (395/976) patients, respectively, during Week 1. Mean change in GERDQ score (n = 1464) improved by Week 4 (−1.70).

Conclusion: Vonoprazan is well tolerated through 8 weeks in patients and improves symptoms in patients with RE in the real-world setting in China (VIEW; NCT04501627).

Keywords

esophagitis, peptic / gastroesophageal reflux disease / potassium competitive acid blockers / vonoprazan

References

[1] J. Lv, D. Liu, S.-Y. Ma, and J. Zhang, “Investigation of Relationships Among Gastroesophageal Reflux Disease Subtypes Using Narrow Band Imaging Magnifying Endoscopy,” World Journal of Gastroenterology 19, no. 45 (2013): 8391–8397.

[2] E. Goosenberg and E. S. Vadakekut, “Gastroesophageal Reflux Disease (GERD) [Updated July 6, 2025],” in StatPearls [Internet] (StatPearls Publishing, 2026).

[3] P. O. Katz, K. B. Dunbar, F. H. Schnoll-Sussman, K. B. Greer, R. Yadlapati, and S. J. Spechler, “ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease,” American Journal of Gastroenterology 117, no. 1 (2022): 27–56.

[4] J. M. Garza and A. Kaul, “Gastroesophageal Reflux, Eosinophilic Esophagitis, and Foreign Body,” Pediatric Clinics of North America 57, no. 6 (2010): 1331–1345.

[5] P. J. Kahrilas, K. W. Altman, A. B. Chang, et al., “Chronic Cough Due to Gastroesophageal Reflux in Adults: CHEST Guideline and Expert Panel Report,” Chest 150, no. 6 (2016): 1341–1360.

[6] J. P. Parsons and J. G. Mastronarde, “Gastroesophageal Reflux Disease and Asthma,” Current Opinion in Pulmonary Medicine 16, no. 1 (2010): 60–63.

[7] J. A. Marsicano, P. G. de Moura-Grec, R. C. S. Bonato, M. de Carvalho Sales-Peres, A. Sales-Peres, and S. H. de Carvalho Sales-Peres, “Gastroesophageal Reflux, Dental Erosion, and Halitosis in Epidemiological Surveys: A Systematic Review,” European Journal of Gastroenterology & Hepatology 25, no. 2 (2013): 135–141.

[8] S. Weissman, A. Chris-Olaiya, A. T. Weber, et al., “Real-World Prevalence of Endoscopic Findings in Patients With Gastroesophageal Reflux Symptoms: A Cross-Sectional Study,” Endoscopy International Open 10, no. 4 (2022): E342–E346.

[9] P. Maresova, L. Rezny, J. Hruska, B. Klimova, L. L. Swanstrom, and K. Kuca, “Diagnosis and Treatment of Patients With Gastroesophageal Reflux Disease — A Systematic Review of Cost-Effectiveness and Economic Burden,” BMC Health Services Research 24, no. 1 (2024): 1351, https://doi.org/10.1186/s12913-024-11781-8.

[10] D. Zou, J. He, X. Ma, et al., “Epidemiology of Symptom-Defined Gastroesophageal Reflux Disease and Reflux Esophagitis: The Systematic Investigation of Gastrointestinal Diseases in China (SILC),” Scandinavian Journal of Gastroenterology 46, no. 2 (2011): 133–141.

[11] Y. Xiao, S. Zhang, N. Dai, et al., “Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Efficacy and Safety of Vonoprazan Compared With Lansoprazole in Asian Patients With Erosive Oesophagitis,” Gut 69, no. 2 (2020): 224–230.

[12] R. Hunt, D. Armstrong, P. Katelaris, et al., “World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease,” Journal of Clinical Gastroenterology 51, no. 6 (2017): 467–478.

[13] K. Ashida, Y. Sakurai, T. Hori, et al., “Randomised Clinical Trial: Vonoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Lansoprazole for the Healing of Erosive Oesophagitis,” Alimentary Pharmacology & Therapeutics 43, no. 2 (2016): 240–251.

[14] Y. Xue, X. Qin, L. Zhou, et al., “A Randomized, Double Blind, Controlled, Multi Center Study of Ilaparazole in the Treatment of Reflux Esophagitis—Phase III Clinical Trial,” Contemporary Clinical Trials 68 (2018): 67–71.

[15] K. Higuchi, T. Joh, K. Nakada, and K. Haruma, “Is Proton Pump Inhibitor Therapy for Reflux Esophagitis Sufficient?: A Large Real-World Survey of Japanese Patients,” Internal Medicine 52, no. 13 (2013): 1447–1454.

[16] J. Gerloff, A. Mignot, H. Barth, and K. Heintze, “Pharmacokinetics and Absolute Bioavailability of Lansoprazole,” European Journal of Clinical Pharmacology 50, no. 4 (1996): 293–297.

[17] T. Piche and J. P. Galmiche, “Pharmacological Targets in Gastro-Oesophageal Reflux Disease,” Basic & Clinical Pharmacology & Toxicology 97, no. 6 (2005): 333–341.

[18] G. N. Tytgat, “Shortcomings of the First-Generation Proton Pump Inhibitors,” European Journal of Gastroenterology & Hepatology 13, no. Suppl 1 (2001): S29–S33.

[19] R. Dickman, C. Maradey-Romero, R. Gingold-Belfer, and R. Fass, “Unmet Needs in the Treatment of Gastroesophageal Reflux Disease,” Journal of Neurogastroenterology and Motility 21, no. 3 (2015): 309–319.

[20] L. Laine, P. Sharma, D. J. Mulford, et al., “Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects,” American Journal of Gastroenterology 117, no. 7 (2022): 1158–1161.

[21] E. St. Onge and B. Phillips, “Vonoprazan: A New Potassium-Competitive Acid Blocker,” Journal of Pharmacy Technology 39, no. 3 (2023): 139–146.

[22] I. Martinucci, C. Blandizzi, G. Bodini, et al., “Vonoprazan Fumarate for the Management of Acid-Related Diseases,” Expert Opinion on Pharmacotherapy 18, no. 11 (2017): 1145–1152.

[23] D. R. Scott, K. B. Munson, E. A. Marcus, N. W. G. Lambrecht, and G. Sachs, “The Binding Selectivity of Vonoprazan (TAK-438) to the Gastric H⁺,K⁺-ATPase,” Alimentary Pharmacology and Therapeutics 42, no. 11–12 (2015): 1315–1326.

[24] U.S. Food and Drug Administration, “Vonoprazan,” 2023, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215151s000lbl.pdf.

[25] A. Patel, L. Laine, P. Moayyedi, and J. Wu, “AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review,” Gastroenterology 167, no. 7 (2024): 1228–1238.

[26] K. Andersson and E. Carlsson, “Potassium-Competitive Acid Blockade: A New Therapeutic Strategy in Acid-Related Diseases,” Pharmacology & Therapeutics 108, no. 3 (2005): 294–307.

[27] Y. Sakurai, A. Nishimura, G. Kennedy, et al., “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects,” Clinical and Translational Gastroenterology 6, no. 6 (2015): e94, https://doi.org/10.1038/ctg.2015.18.

[28] Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, “Report on the Deliberation Results,” 2014, https://www.pmda.go.jp/files/000211075.pdf.

[29] S. Han, Z. Deng, K. Cheung, et al., “Vonoprazan-Based Triple and Dual Therapy Versus Bismuth-Based Quadruple Therapy for Helicobacter pylori Infection in China: A Three-Arm, Randomised Clinical Trial Protocol,” BMC Gastroenterology 23, no. 1 (2023): 231, https://doi.org/10.1186/s12876-023-02872-7.

[30] “Takeda's Takecab Approved in China to Eradicate HP,” NAVLIN Daily 2023, https://www.navlindaily.com/article/19626/takeda-s-takecab-approved-in-china-to-eradicate-hp.

[31] Takeda Pharmaceutical Company Limited, “U.S. Securities and Exchange Commission FORM 20-F FY2023,” https://assets-dam.takeda.com/image/upload/Global/Investor/form20-f/E_FY2023_Form_20-F.pdf.

[32] Y. Xiao, J. Qian, S. Zhang, et al., “Vonoprazan 10 mg or 20 mg vs. Lansoprazole 15 mg as Maintenance Therapy in Asian Patients With Healed Erosive Esophagitis: A Randomized Controlled Trial,” Chinese Medical Journal 137, no. 8 (2024): 962–971.

[33] Takeda Pharmaceutical Company Limited, “Vonoprazan Fumarate Tablets,” 2026, https://www.takeda.com.cn/products/. [in Chinese].

[34] R. Jones, O. Junghard, J. Dent, et al., “Development of the GerdQ, A Tool for the Diagnosis and Management of Gastro-Oesophageal Reflux Disease in Primary Care,” Alimentary Pharmacology & Therapeutics 30, no. 10 (2009): 1030–1080.

[35] D. J. Buysse, C. F. Reynolds, 3rd, T. H. Monk, S. R. Berman, and D. J. Kupfer, “The Pittsburgh Sleep Quality Index: A New Instrument for Psychiatric Practice and Research,” Psychiatry Research 28, no. 2 (1989): 193–213.

[36] EuroQol Group, “EuroQol—A New Facility for the Measurement of Health-Related Quality of Life,” Health Policy 16, no. 3 (1990): 199–208.

[37] N. Devlin, D. Parkin, and B. Janssen, Methods for Analysing and Reporting EQ-5D Data (Springer, 2020).

[38] L. Laine, K. DeVault, P. Katz, et al., “Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial,” Gastroenterology 164, no. 1 (2023): 61–71.

[39] M. F. Vaezi, S. Brunton, A. M. Fendrick, et al., “Patient Journey in Erosive Oesophagitis: Real-World Perspectives From US Physicians and Patients,” BMJ Open Gastroenterology 9, no. 1 (2022): e000941, https://doi.org/10.1136/bmjgast-2022-000941.

[40] R. Fass, M. Vaezi, P. Sharma, et al., “Randomised Clinical Trial: Efficacy and Safety of on-Demand Vonoprazan Versus Placebo for Non-Erosive Reflux Disease,” Alimentary Pharmacology & Therapeutics 58, no. 10 (2023): 1016–1027.

[41] L. Laine, S. Spechler, R. Yadlapati, et al., “Vonoprazan Is Efficacious for Treatment of Heartburn in Non-Erosive Reflux Disease: A Randomized Trial,” Clinical Gastroenterology and Hepatology 22, no. 11 (2024): 2211–2220.e10.

[42] R. Tutuian and D. O. Castell, “Nocturnal Acid Breakthrough — Approach to Management,” MedGenMed 6, no. 4 (2004): 11.

[43] Institute of Medicine and National Research Council, Saving Women's Lives: Strategies for Improving Breast Cancer Detection and Diagnosis: A Breast Cancer Research Foundation and Institute of Medicine Symposium (National Academies Press, 2005), https://doi.org/10.17226/11156.

[44] K. G. Lockwood, P. R. Kulkarni, J. Paruthi, et al., “Evaluating a New Digital App-Based Program for Heart Health: Feasibility and Acceptability Pilot Study,” JMIR Formative Research 8 (2024): e50446, https://doi.org/10.2196/50446.

[45] S. Malay and K. C. Chung, “The Choice of Controls for Providing Validity and Evidence in Clinical Research,” Plastic and Reconstructive Surgery 130, no. 4 (2012): 959–965.

[46] J. K. Paulus, I. J. Dahabreh, E. M. Balk, E. E. Avendano, J. Lau, and S. Ip, “Opportunities and Challenges in Using Studies Without a Control Group in Comparative Effectiveness Reviews,” Research Synthesis Methods 5, no. 2 (2014): 152–161.

[47] B. Wang, J. Pan, T. Zhang, et al., “Protocol for CHAMPION Study: A Prospective Study of Maximal-Cytoreductive Therapies for Patients With De Novo Metastatic Hormone-Sensitive Prostate Cancer Who Achieve Oligopersistent Metastases During Systemic Treatment With Apalutamide Plus Androgen Deprivation Therapy,” BMC Cancer 24, no. 1 (2024): 643, https://doi.org/10.1186/s12885-024-12395-3.

Rights & permissions

2026 The Author(s). Journal of Digestive Diseases published by Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.